Xiezhuo Tiaozhi formula inhibits macrophage pyroptosis in the non-alcoholic fatty liver disease by targeting the SIRT1 pathway

被引:3
|
作者
Tian, Lulu [1 ]
Chen, Jing [1 ]
Yang, Meiqi [2 ]
Chen, Lin [1 ]
Qiu, Jiannan [1 ]
Jiang, Yuwei [1 ]
Tan, Xiaolong [1 ]
Qian, Qianyu [1 ]
Liang, Xiao [3 ,4 ]
Dou, Xiaobing [1 ,5 ]
机构
[1] Zhejiang Chinese Med Univ, Sch Life Sci, Hangzhou, Zhejiang, Peoples R China
[2] Liaoning Univ Tradit Chinese Med, Xinglin Coll, Shenyang, Liaoning, Peoples R China
[3] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Gen Surg, Hangzhou, Zhejiang, Peoples R China
[4] 453 Stadium Rd, Hangzhou 310053, Zhejiang, Peoples R China
[5] 548 Binwen Rd, Hangzhou 310053, Zhejiang, Peoples R China
关键词
Xiezhuo Tiaozhi formula; Non-alcoholic fatty liver disease; Macrophage pyroptosis; Macrophage polarization; SIRT1; pathway; GASDERMIN-D; IN-VITRO; POLARIZATION; NAFLD; INFLAMMATION;
D O I
10.1016/j.phymed.2024.155776
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Background: Non-alcoholic fatty liver disease (NAFLD) is a challenging disease to interfere with and represents a potential long -term risk factor for hepatic fibrosis and liver cancer. The Xiezhuo Tiaozhi (XZTZ) formula, a water extract from crude herbs, has been widely used as an anti-NAFLD agent through clinical observation. However, the underlying pharmacological mechanisms of the XZTZ formula and its impact on the potential pathways against NAFLD have not been elucidated. Purpose: Our study aims to investigate the pharmacological effects and underlying regulatory mechanisms of the XZTZ formula to treat NAFLD. Methods: The possible active components and pharmacological mechanisms of the XZTZ formula against NAFLD were identified using ultra -performance liquid chromatography-quadrupole time -of -flight mass spectrometry (UPLC-Q-TOF/MS) and molecular docking. To further explore the potential mechanisms, forty-eight 6-week-old male C57BL/6 J mice were given individual attention with high -fat and high-sugar diet (HFHSD) or relevant control (Ctrl) diets for 16 weeks to successfully construct a NAFLD mouse model. Subsequently, the levels of serum biochemicals, pathological changes in the liver, and pyroptosis levels were assessed in mice to investigate the therapeutic effects of the XZTZ formula. Further, LPS-induced RAW264.7 cells and Immortalized Mouse Kupffer cells (ImKC) were used to verify the potential mechanisms of the XZTZ formula against NAFLD in vitro . Results: We identified 7 chemical compounds and 2 potential therapeutic targets as plausible therapeutic points for the treatment of NAFLD using the XZTZ formula. Subsequent histopathological analysis revealed marked hepatic steatosis and lipid accumulation in the HFHSD mice liver, while conditions were effectively ameliorated by administration of the XZTZ formula. Additionally, our work demonstrated that the XZTZ formula could attenuate M1 polarization, promote M2 polarization, and suppress pyroptosis via the SIRT1 pathway in tissue samples. Moreover, validation performed through LPS-induced RAW264.7 and ImKC cells by showing that silencing SIRT1 weaken the effects of the XZTZ formula on relative pyroptosis affirmed that its role was associated with the SIRT1 pathway in macrophage. Conclusion: These findings suggest that the XZTZ formula alleviated hepatic steatosis and lipid accumulation in NAFLD mice. These ameliorations are associated with mechanisms involving the attenuation of M1 polarization, promotion of M2 polarization, and anti-pyroptosis effects through the SIRT1 pathway.
引用
收藏
页数:17
相关论文
共 50 条
  • [1] Role of the AMPK/SIRT1 pathway in non-alcoholic fatty liver disease (Review)
    Anggreini, Putri
    Kuncoro, Hadi
    Sumiwi, Sri Adi
    Levita, Jutti
    MOLECULAR MEDICINE REPORTS, 2023, 27 (02)
  • [2] A Potential Treatment of Non-Alcoholic Fatty Liver Disease with SIRT1 Activators
    Colak, Yasar
    Yesil, Atakan
    Mutlu, Hasan Huseyin
    Caklili, Ozge Telci
    Ulasoglu, Celal
    Senates, Ebubekir
    Takir, Mumtaz
    Kostek, Osman
    Yilmaz, Yusuf
    Enc, Feruze Yilmaz
    Tasan, Guralp
    Tuncer, Ilyas
    JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2014, 23 (03) : 311 - 319
  • [3] Plasma levels of SIRT1 associate with non-alcoholic fatty liver disease in obese patients
    Mariani, Stefania
    Fiore, Daniela
    Basciani, Sabrina
    Persichetti, Agnese
    Contini, Savina
    Lubrano, Carla
    Salvatori, Luisa
    Lenzi, Andrea
    Gnessi, Lucio
    ENDOCRINE, 2015, 49 (03) : 711 - 716
  • [4] Plasma levels of SIRT1 associate with non-alcoholic fatty liver disease in obese patients
    Stefania Mariani
    Daniela Fiore
    Sabrina Basciani
    Agnese Persichetti
    Savina Contini
    Carla Lubrano
    Luisa Salvatori
    Andrea Lenzi
    Lucio Gnessi
    Endocrine, 2015, 49 : 711 - 716
  • [5] miR-34a regulates lipid metabolism by targeting SIRT1 in non-alcoholic fatty liver disease with iron overload
    Wang, Li
    Sun, Mengyun
    Cao, Yue
    Ma, Lingyu
    Shen, Yang
    Velikanova, Arina Alekseevna
    Li, Xianan
    Sun, Changhao
    Zhao, Yan
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2020, 695
  • [6] Therapeutic effects of isosteviol sodium on non-alcoholic fatty liver disease by regulating autophagy via Sirt1/AMPK pathway
    Ying Mei
    Hui Hu
    Liangjun Deng
    Xiaoou Sun
    Wen Tan
    Scientific Reports, 12
  • [7] Therapeutic effects of isosteviol sodium on non-alcoholic fatty liver disease by regulating autophagy via Sirt1/AMPK pathway
    Mei, Ying
    Hu, Hui
    Deng, Liangjun
    Sun, Xiaoou
    Tan, Wen
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [8] 11β-HSD1 Inhibitor Alleviates Non-Alcoholic Fatty Liver Disease by Activating the AMPK/SIRT1 Signaling Pathway
    Chen, Ying
    Li, Jiali
    Zhang, Meng
    Yang, Wei
    Qin, Wenqi
    Zheng, Qinzhou
    Chu, Yanhui
    Wu, Yan
    Wu, Dan
    Yuan, Xiaohuan
    NUTRIENTS, 2022, 14 (11)
  • [9] ROLE OF SIRT1 AND AMPK IN THE DEVELOPMENT OF INSULIN RESISTANCE ASSOCIATED TO NON-ALCOHOLIC FATTY LIVER DISEASE
    Silvestre, M.
    Sugden, M.
    Viollet, B.
    Holness, M.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S499 - S499
  • [10] Silibinin Restores NAD+ Levels and Induces the SIRT1/AMPK Pathway in Non-Alcoholic Fatty Liver
    Salomone, Federico
    Barbagallo, Ignazio
    Godos, Justyna
    Lembo, Vincenzo
    Currenti, Walter
    Cina, Diana
    Avola, Roberto
    D'Orazio, Nicolantonio
    Morisco, Filomena
    Galvano, Fabio
    Li Volti, Giovanni
    NUTRIENTS, 2017, 9 (10):